Bionano Genomics reports Q3 2026 revenue growth and advances in clinical adoption of genome mapping.

Bionano Genomics announced a 12% revenue increase to $8.3 million in Q3 2026, driven by a 24% rise in consumables sales and an 18% increase in flowcell units sold. The company highlighted progress in reimbursement pathways and regulatory approvals, supporting broader clinical use of its optical genome mapping technology. With new peer-reviewed studies validating its clinical value, Bionano expects sustained growth into 2027. The company reaffirmed its full-year 2026 revenue guidance of $31 to $33 million.

As of Nov 11, 2026 04:02 WIB, Bionano Genomics (BNGO) is trading at USD 1.25 on Pluang, up 7.76% for the day. This price is closer to its 52-week low of $1.06 than its high of $1.85, indicating room for growth compared to its past year range. The stock's market cap stands at $16.35 million, with all recent Pluang orders being buys, reflecting strong investor interest at this level.